Short Interest in IQVIA Holdings Inc. (NYSE:IQV) Drops By 25.5%

IQVIA Holdings Inc. (NYSE:IQV) was the recipient of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 3,792,023 shares, a drop of 25.5% from the February 12th total of 5,088,012 shares. Approximately 2.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,197,832 shares, the short-interest ratio is currently 1.2 days. Based on an average daily trading volume, of 3,197,832 shares, the short-interest ratio is currently 1.2 days. Approximately 2.3% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Eubel Brady & Suttman Asset Management Inc. acquired a new stake in shares of IQVIA during the 3rd quarter worth about $14,278,000. Eagle Rock Investment Company LLC boosted its position in IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares in the last quarter. OPTIMAS CAPITAL Ltd bought a new stake in IQVIA during the third quarter worth about $4,008,000. Amundi increased its holdings in shares of IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after buying an additional 405,250 shares in the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd bought a new position in shares of IQVIA in the third quarter valued at approximately $7,368,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

NYSE:IQV traded up $1.85 during trading hours on Friday, reaching $164.78. 1,600,377 shares of the company’s stock were exchanged, compared to its average volume of 2,423,808. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The company has a market capitalization of $27.96 billion, a P/E ratio of 20.96, a price-to-earnings-growth ratio of 1.59 and a beta of 1.39. IQVIA has a 12 month low of $134.65 and a 12 month high of $247.04. The business’s 50-day simple moving average is $201.58 and its two-hundred day simple moving average is $206.80.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on IQV shares. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a report on Friday, March 6th. Evercore restated an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a research report on Thursday, February 5th. BMO Capital Markets set a $250.00 price target on IQVIA in a research note on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.